Compare Immunovant Inc. Common Stock (IMVT) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs NetEase Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while NetEase Inc trades at $122.32 (market cap $76.90B). The key difference: NetEase Inc is far larger — about 11.6× Immunovant Inc. Common Stock's market cap, and NetEase Inc pays a 2.43% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and NetEase Inc for 74 Days on average.
| IMVT | NTES | |
|---|---|---|
Market Cap | $6.62B | $76.90B |
Volume | 1,131,364 | 494,839 |
Sector | Health | Technology |
52-Week High | $44.96 | $152.85 |
52-Week Low | $17.03 | $109.26 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $5.72B | $52.62B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTES trades at $119.60, up 0.45% today, with a neutral technical signal. The company reported Q2 2026 revenue of $4.4 billion, up 8% year-over-year, though EPS missed estimates due to investment losses. Gross margins improved significantly, and the balance sheet remains strong with $137.58 billion in cash. Revenue growth has been steady, with 2025 revenue reaching $112.63 billion and net income at $33.76 billion.
The outlook is positive given strong profitability, a robust balance sheet, and analyst consensus favoring a buy rating with a $168 price target. Risks include earnings volatility, competitive pressures in gaming, and macroeconomic headwinds affecting Chinese tech stocks. The stock presents a value opportunity with a P/E of 16.06, below industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
